Tag: CBD
-
![Pure Extracts (PULL.C) begins mushroom build-out]()
Pure Extracts (PULL.C) begins mushroom build-out
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise.
-
![Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver]()
Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies.
-
![Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms]()
Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
-
![Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test]()
Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection
-
![Plus Products (PLUS.C) 71% costs turnaround shows legitimacy in management, anchors growth]()
Plus Products (PLUS.C) 71% costs turnaround shows legitimacy in management, anchors growth
Esteemed California cannabis gummies maker Plus Products (PLUS.C) issued quarterly financials Thursday showing a substantial turnaround as their Nevada and national CBD growth plans take hold. After a 10c per share loss in Q1, the company presented a mere 1c per share loss in Q2, with $4.3 million in revenue, despite COVID-driven slowdowns in Nevada.…
-
![Willow Biosciences (WLLW.T) takes the romance (and risk) out of cannabinoid production]()
Willow Biosciences (WLLW.T) takes the romance (and risk) out of cannabinoid production
Willow Biosciences (WLLW.T) is a Canadian biotech company based in Vancouver, BC, that is using “a proprietary yeast strain laboratory process” to produce commercial quantities of CBD and CBG”.
-
![Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling]()
Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
-
XPhyto (XPHY.C) advances a COVID-screener that works like a pregnancy test
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
-
Plus Products (PLUS.C) just parachuted right into my world
Heimark has a track record of rigorous market research prior to launching products. This research-based approach has reaped dividends in market penetration and revenue growth.
